Targeted therapy for malignant gliomas.

摘要: The identification of markers that are associated with tumour but not normal tissue has allowed the development highly-specific targeted therapies. Monoclonal antibodies, either alone or linked to radioisotopes toxins, have provided a powerful tool for research, as well basis promising therapeutic agents less side effects than standard radiotherapy chemotherapy. A new class drugs, tyrosine kinase inhibitors, which interfere function key molecules in cancer-promoting pathways, had dramatic effect haematological malignancy and being trialled solid tumours, including glioma. Although problem achieving specific, high-level delivery these various tumours brain remains major issue, encouraging early results some support attractive theoretical principles this paradigm. Further work identify molecular targets develop exploiting them, is needed, confirmation their safety efficacy by clinical trials.